Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Arterra Bioscience SpA ( (IT:ARBS) ) just unveiled an update.
Arterra Bioscience’s shareholders approved the 2025 financial statements, highlighting a 16.12% rise in production value to €6.1 million, stronger profitability with EBITDA up nearly 30% to €2.2 million, EBIT of €2.1 million, and net profit of about €2.0 million, 50.09% higher than 2024, alongside a positive net financial position of €6.2 million and higher shareholders’ equity. The meeting also approved a dividend of €0.15 per share for 2025, with the remainder of profits allocated to retained earnings, and appointed KPMG S.p.A. as statutory auditor for the 2026–2028 period, reinforcing governance and oversight as the company continues its growth trajectory.
More about Arterra Bioscience SpA
Arterra Bioscience S.p.A. is a Naples-based green biotechnology company focused on research and development in the biotech sector and listed on Euronext Growth Milan since 2019. The company develops innovative biotech solutions and leverages a solid financial structure to support growth in its specialized market niche.
Average Trading Volume: 8,534
Technical Sentiment Signal: Strong Buy
Current Market Cap: €20.37M
See more insights into ARBS stock on TipRanks’ Stock Analysis page.